Spyre Therapeutics (SYRE) announced that it has initiated dosing in a healthy volunteer, Phase 1 clinical trial of its investigational ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic ...

Wolfe Research initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $27 price target The company is an early stage ...

Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance ...

Wolfe Research assumed coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) in a research report issued ...

Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million public offering Continued ...

Victory Capital Management Inc. purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) ...

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in ...

About Spyre Therapeutics Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining ...

Try Now>> See the top stocks recommended by analysts >> Read More on SYRE: Spyre Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...